Based on the guideline-recommended by Kidney Disease: Improving Global Outcomes (KDIGO), Vitamin D Receptor Activators (VDRA) and calcimimetics are the optimal strategies of SHPT treatment, complemented to decrease PTH, prevent hypocalcemia, improve survival, and reduce cardiovascular disease (15, 21). This evidence concerns the gene PTH and cardiovascular disorder.